BNP/PUT/GILEAD SCIENCES/60/0.1/20.12.24 Stock

DE000PC5C5A0

Market Closed - Boerse Frankfurt Warrants 15:50:25 2024-07-05 EDT
0.18 ^EUR	-5.26%

Current month	+20.00%
1 month	-35.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart BNP/PUT/GILEAD SCIENCES/60/0.1/20.12.24

Latest news about GILEAD SCIENCES, INC.

HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis]	07-03	AQ
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	07-01	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	07-01	CI
Gilead Benefit Helps Employees Navigate Cancer Care	07-01	AQ

More news

Quotes 5-day view

Date	Price	Change
24-07-05	0.18	-5.26%
24-07-04	0.19	+11.76%
24-07-03	0.17	+13.33%
24-07-02	0.15	+7.14%
24-07-01	0.14	-6.67%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 03:50 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	GILEAD SCIENCES, INC.
Issuer	BNP Paribas
WKN	PC5C5A
ISIN	DE000PC5C5A0
Date issued	2024-02-21
Strike	60 $
Maturity	2024-12-20 (168 Days)
Parity	10 : 1
Emission price	0.21 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.35 €
Lowest since issue	0.11 €
Spread	0.01 €
Spread %	5.26%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company